Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1

Interventions

Specimen Handling 21Magnetic Resonance Spectroscopy 17Carboplatin 16Gemcitabine 14pembrolizumab 11Paclitaxel 11Cisplatin 11Interviews as Topic 10Injections 10fludarabine 9Radiotherapy 8Oxaliplatin 8Nivolumab 8Dexamethasone 8Cyclophosphamide 8Irinotecan 7Fluorouracil 7Bortezomib 7Biopsy 7Bevacizumab 7toripalimab 6Radiosurgery 5Pemetrexed 5Leucovorin 5Capecitabine 5130-nm albumin-bound paclitaxel 5trastuzumab deruxtecan 4liposomal doxorubicin 4cemiplimab 4X-Rays 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × sugemalimab × 30 days × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡